ADAM-9, ADAM-15, and ADAM-17 are upregulated in macrophages in advanced human atherosclerotic plaques in aorta and carotid and femoral arteries—Tampere vascular study

Background and aims. The expression of disintegrin and metalloprotease ADAM-9, ADAM-15, and ADAM-17 has been associated with cell-cell, cell-platelet, and cell-matrix interactions and inflammation. They are possibly implicated in the pathophysiology of atherosclerosis. Methods and results. Whole-genome expression array and quantitative real-time polymerase chain reaction (PCR) analysis confirmed that ADAM-9, ADAM-15, and ADAM-17 are upregulated in advanced human atherosclerotic lesions in samples from carotid, aortic, and femoral territories compared to samples from internal thoracic artery (ITA) free of atherosclerotic plaques. Western analysis indicated that the majority of these ADAMs were in the catalytically active form. ADAM-9, ADAM-15, and ADAM-17-expressing cells were shown to co-localize with CD68-positive cells of monocytic origin in the atherosclerotic plaques using immunohistochemistry and double-staining immunofluorescence analysis. Co-localization was demonstrated in all vascular territories. In the carotid territory, cells expressing the ADAMs co-distributed also with smooth muscle cells and, in femoral territory, with CD31-positive endothelial cells, indicating that the ADAM expression pattern depends on vascular bed territory. Conclusions. Present findings provide strong evidence for the involvement of catalytically active ADAM-9, ADAM-15, and ADAM-17 in advanced atherosclerosis, most notably associated with cells of monocytic origin.

[1]  M. Gawaz,et al.  ADAM15 is an adhesion receptor for platelet GPIIb-IIIa and induces platelet activation , 2005, Thrombosis and Haemostasis.

[2]  W D Wagner,et al.  A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[3]  S. Miyamoto,et al.  Heparin‐binding epidermal growth factor‐like growth factor as a novel targeting molecule for cancer therapy , 2006, Cancer science.

[4]  C. Maury,et al.  Circulating tumour necrosis factor‐α (cachectin) in myocardial infarction , 1989 .

[5]  M. Pelto-huikko,et al.  Shedding light on ADAM metalloproteinases. , 2005, Trends in biochemical sciences.

[6]  M. Netea,et al.  The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. , 2007, Journal of lipid research.

[7]  P. Croucher,et al.  ADAM-9 (MDC-9/meltrin-gamma), a member of the a disintegrin and metalloproteinase family, regulates myeloma-cell-induced interleukin-6 production in osteoblasts by direct interaction with the alpha(v)beta5 integrin. , 2006, Blood.

[8]  J. Wilhelm,et al.  Increased expression of disintegrin‐metalloproteinases ADAM‐15 and ADAM‐9 following upregulation of integrins α5β1 and αvβ3 in atherosclerosis , 2003 .

[9]  L. Shaw,et al.  Regulation of cellular interactions with laminin by integrin cytoplasmic domains: the A and B structural variants of the alpha 6 beta 1 integrin differentially modulate the adhesive strength, morphology, and migration of macrophages. , 1994, Molecular biology of the cell.

[10]  T. Wolfsberg,et al.  ADAM, a widely distributed and developmentally regulated gene family encoding membrane proteins with a disintegrin and metalloprotease domain. , 1995, Developmental biology.

[11]  M. Lambert,et al.  Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α , 1997, Nature.

[12]  K. Horiuchi,et al.  Potential Role for ADAM15 in Pathological Neovascularization in Mice , 2003, Molecular and Cellular Biology.

[13]  F. Sánchez‐Madrid,et al.  Expression and Regulation of the Metalloproteinase ADAM-8 during Human Neutrophil Pathophysiological Activation and Its Catalytic Activity on L-Selectin Shedding1 , 2007, The Journal of Immunology.

[14]  M. Fishbein,et al.  Detection and localization of tumor necrosis factor in human atheroma. , 1990, The American journal of cardiology.

[15]  S. Fuller,et al.  Hepatitis B surface antigen assembles in a post-ER, pre-Golgi compartment , 1992, The Journal of cell biology.

[16]  E. Mekada,et al.  A metalloprotease–disintegrin, MDC9/meltrin‐γ/ADAM9 and PKCδ are involved in TPA‐induced ectodomain shedding of membrane‐anchored heparin‐binding EGF‐like growth factor , 1998, The EMBO journal.

[17]  Nicole Nelson,et al.  A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells , 1997, Nature.

[18]  G. Ferns,et al.  The epidermal growth factor receptors and their family of ligands: their putative role in atherogenesis. , 2006, Atherosclerosis.

[19]  M. Key,et al.  Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. , 1991, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[20]  Y. Takada,et al.  Specific interaction of the recombinant disintegrin-like domain of MDC-15 (metargidin, ADAM-15) with integrin alphavbeta3. , 1998, The Journal of biological chemistry.

[21]  R. Brentani,et al.  alpha6beta1-Integrin, a major cell surface carrier of beta1-6-branched oligosaccharides, mediates migration of EJ-ras-transformed fibroblasts on laminin-1 independently of its glycosylation state. , 1996, Cancer Research.

[22]  M. Alessi,et al.  The TNF alpha converting enzyme (TACE/ADAM17) is expressed in the atherosclerotic lesions of apolipoprotein E-deficient mice: possible contribution to elevated plasma levels of soluble TNF alpha receptors. , 2006, Atherosclerosis.

[23]  B. Baker,et al.  ADAM17 but not ADAM10 mediates tumor necrosis factor-alpha and L-selectin shedding from leukocyte membranes. , 2001, Antisense & nucleic acid drug development.

[24]  R. Brentani,et al.  α6β1-Integrin, a Major Cell Surface Carrier of β1-6-branched Oligosaccharides, Mediates Migration of EJ-ras-transformed Fibroblasts on Laminin-1 Independently of Its Glycosylation State , 1996 .

[25]  Y. Takada,et al.  Specific Interaction of the Recombinant Disintegrin-like Domain of MDC-15 (Metargidin, ADAM-15) with Integrin αvβ3* , 1998, The Journal of Biological Chemistry.

[26]  R. Ross,et al.  Expression of a disintegrin‐like protein in cultured human vascular cells and in vivo , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  C. Blobel,et al.  ADAMs: key components in EGFR signalling and development , 2005, Nature Reviews Molecular Cell Biology.

[28]  D. Seals,et al.  The ADAMs family of metalloproteases: multidomain proteins with multiple functions. , 2003, Genes & development.

[29]  J. Ramires,et al.  Serial Changes in Plasma Levels of Cytokines in Patients with Coronary Artery Disease , 2005, Vascular health and risk management.

[30]  P. Slocombe,et al.  Meltrin gamma(ADAM-9) mediates cellular adhesion through alpha(6)beta(1 )integrin, leading to a marked induction of fibroblast cell motility. , 2000, Journal of cell science.

[31]  C. Maury,et al.  Circulating tumour necrosis factor-alpha (cachectin) in myocardial infarction. , 1989, Journal of internal medicine.

[32]  M. Alessi,et al.  Microparticles of human atherosclerotic plaques enhance the shedding of the tumor necrosis factor-alpha converting enzyme/ADAM17 substrates, tumor necrosis factor and tumor necrosis factor receptor-1. , 2007, The American journal of pathology.

[33]  Marko Sysi-Aho,et al.  A Systems Biology Strategy Reveals Biological Pathways and Plasma Biomarker Candidates for Potentially Toxic Statin-Induced Changes in Muscle , 2006, PloS one.

[34]  J. Peschon,et al.  TNF-α-Converting Enzyme Cleaves the Macrophage Colony-Stimulating Factor Receptor in Macrophages Undergoing Activation1 , 2001, The Journal of Immunology.

[35]  B. Castner,et al.  A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. , 1997, Nature.

[36]  A. Sonnenberg,et al.  Cre-loxP–mediated Inactivation of the α6A Integrin Splice Variant In Vivo: Evidence for a Specific Functional Role of α6A in Lymphocyte Migration but Not in Heart Development , 1998, The Journal of cell biology.

[37]  P. Croucher,et al.  ADAM-9 (mdc-9/meltrin-γ), a member of the a disintegrin and metalloproteinase family, regulates myeloma cell induced interleukin-6 production in osteoblasts by direct interaction with the αvβ5-integrin , 2006 .

[38]  E. P. Moiseeva.  Adhesion receptors of vascular smooth muscle cells and their functions. , 2001, Cardiovascular research.

[39]  J. Bartsch,et al.  Therapeutic benefits from targeting of ADAM family members. , 2004, Biochemistry.

[40]  J. Wilhelm,et al.  Increased expression of disintegrin-metalloproteinases ADAM-15 and ADAM-9 following upregulation of integrins alpha5beta1 and alphavbeta3 in atherosclerosis. , 2003, Journal of cellular biochemistry.

[41]  P. Slocombe,et al.  Interaction of metargidin (ADAM-15) with alphavbeta3 and alpha5beta1 integrins on different haemopoietic cells. , 1999, Journal of cell science.

[42]  Didier Merlin,et al.  ADAM‐15: a metalloprotease that mediates inflammation , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[43]  M. Denis,et al.  ADAM15 upregulation and interaction with multiple binding partners in inflammatory bowel disease , 2006, Laboratory Investigation.